Table 1.
Patient-reported outcomes of 80 patients affected by atopic dermatitis treated with dupilumab during the COVID-19 pandemic
| Patient-reported outcomes | ||
|---|---|---|
| NRS pruritus median [range] | ||
| - T1 | 2 [0–8] | P = .62189* |
| -T2 | 2 [0–8] | ns |
| -T3 | 2 [0–7] | |
| NRS sleep median [range] | ||
| -T1 | 0 [0–9] | P = .72253* |
| -T2 | 0 [0–7] | ns |
| -T3 | 0 [0–6] | |
| NRS severity median [range] | ||
| -T1 | 2.5 [0–6] | P = .18731* |
| -T2 | 2.5 [0–7] | ns |
| -T3 | 2.5 [0–5] |
COVID-19, coronavirus disease 2019; NRS, numeric rating scale (1-10); ns, not significant.
⁎
Comparison among T1-T2-T3 measurements was performed by using the Friedman test with repeated measures (T1 = February 2020, T2 = March 2020, T3 = April 2020).